This week in drug discovery (15-19 July)
News round-up for 15-19 July by DDW Senior Digital Content Editor Diana Spencer.
The chosen news stories this week all feature therapies that could have significant impact on the future treatment of cancer, particularly haematological malignancies, but also solid tumours.
The top stories:
Bacteriophage study offers new hope in treating GVHD
Researchers from Japan have identified a bacteriophage-derived enzyme that holds promise for future applications in preventing or treating acute graft-versus-host disease (aGVHD).
In vivo testing validates new approach to cancer treatment
In vivo testing has validated Oxford Drug Design’s potential first-in-class approach against multiple tumours, designed using its AI platform.
Swiss Orphan Drug Status for cutaneous T-cell lymphoma drug
The Swiss Agency for Therapeutic Products (SwissMedic) has granted Orphan Drug Status (ODS) to 4SC’s Kinselby (resminostat) for the treatment of cutaneous T-cell lymphoma (CTCL).
Acute myeloid leukaemia drug gets fast-tracked
The US Food and Drug Administration (FDA) has granted Fast Track designation to Sumitomo Pharma’s DSP-5336 for relapsed or refractory acute myeloid leukaemia (AML).
CatalYm raises $150m for cancer therapy visugromab
CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab.